AMPLITUDE boosts radiographic PFS with niraparib in HRR-mutated mCSPC

The phase 3 AMPLITUDE trial was the first study to demonstrate that adding a PARP inhibitor to standard therapy significantly improved radiographic progression-free survival (PFS) in participants with metastatic castration-sensitive prostate cancer (mCSPC) harbouring homologous recombination repair (HRR) gene alterations. Prof. Gerhard Attard (University College London, UK) introduced the AMPLITUDE (NCT04497844) study, which enrolled 696 participants with mCSPC and HRR mutations, randomly assigning them to either PARP inhibitor niraparib plus abiraterone acetate, and prednisone (AAP) or placebo plus AAP. All participants had received no more than 6 months of prior androgen-deprivation therapy and/or 6 cycles of docetaxel [1]. The combination of niraparib and AAP reduced the risk of radiographic progression or death by 37% compared with placebo and AAP (HR 0.63; 95% CI 0.49–0.80; P=0.0001). “...

Please login to read the full text of the article.

If you have no account yet, please register now.

Posted on 30 July 2025